BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22728908)

  • 1. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
    Kishi T; Hirooka Y; Konno S; Sunagawa K
    J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan improves endothelial function in patients with essential hypertension.
    Benndorf RA; Appel D; Maas R; Schwedhelm E; Wenzel UO; Böger RH
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):367-71. PubMed ID: 18049303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and vascular protective effects of telmisartan in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Sawada K
    Hypertens Res; 2006 Aug; 29(8):567-72. PubMed ID: 17137211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
    Shimabukuro M; Tanaka H; Shimabukuro T
    J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
    Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2014 Dec; 27(12):1464-71. PubMed ID: 24871627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
    Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
    Okano Y; Tamura K; Kuji T; Masuda S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2009 May; 31(3):250-8. PubMed ID: 19387901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.
    Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y
    Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
    Tomiyama H; Yamada J; Koji Y; Shiina K; Yoshida M; Yamashina A
    Am J Hypertens; 2007 Dec; 20(12):1305-11. PubMed ID: 18047921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
    Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
    Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
    Tomiyama H; Yambe M; Yamada J; Motobe K; Koji Y; Yoshida M; Shiina K; Yamashina A
    J Hypertens; 2007 Apr; 25(4):883-9. PubMed ID: 17351383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan improves impaired endothelial function in the human coronary artery.
    Iino K; Watanabe H; Iino T; Katsuta M; Koyama T; Kosaka T; Terui G; Ito H
    Coron Artery Dis; 2012 Jun; 23(4):278-83. PubMed ID: 22343799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.
    Shargorodsky M; Hass E; Boaz M; Gavish D; Zimlichman R
    Atherosclerosis; 2008 Mar; 197(1):303-10. PubMed ID: 17588581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
    Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
    Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.